Oncoclínicas do Brasil Serviços Médicos (ONCO3) Q4 2025 earnings summary

Executive summary

• Leadership transition and strategic restructuring in response to a challenging operating environment, with a focus on operational turnaround, cost review, and financial discipline.

• Strategic shift to prioritize outpatient oncology services, divest non-core assets, and reduce exposure to high-risk payors.

• Severe liquidity pressures from major payor defaults (Unimed FERJ: R$864.9M) and Banco Master deposit losses (R$431M), resulting in increased indebtedness and negative working capital.

• R$1.4 billion capital increase via debt-to-equity conversion in Q4 2025 to deleverage and restore operational discipline.

• Net loss reached R$3.67 billion in 2025, driven by operational challenges, asset impairments, and credit losses.

Financial highlights

• Net revenue for 2025 was R$5.74 billion, down 7.8% year-over-year, with gross revenue at R$6.3 billion.

• Adjusted EBITDA for 2025 was R$831.0 million (margin 14.5%), down 32% year-over-year; 4Q25 Adjusted EBITDA was R$238.8 million (margin 17.4%).

• Gross margin for the year was 31.2%, with quarterly cash gross margin reaching 36.8%.

• Net loss for 2025 was R$3.67 billion, compared to R$717 million in 2024.

• Cash position at year-end was R$509 million, with negative working capital of R$2.3 billion.

Outlook and guidance

• Management projects net revenue of R$6.29 billion and EBITDA ex-PILP of R$1.08 billion for 2026, with a gross margin of 33.4%.

• Focus remains on core oncology, operational efficiency, deleveraging, and successful debt reprofiling.

• Ongoing negotiations with creditors to restructure debt and align amortization with cash flow generation.